标题
Monoclonal antibodies therapies for ovarian cancer
作者
关键词
-
出版物
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 13, Issue 5, Pages 739-764
出版商
Informa Healthcare
发表日期
2013-02-04
DOI
10.1517/14712598.2013.767328
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy
- (2017) K. A. Gelmon et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
- (2017) T. D. Tillmanns et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study.
- (2017) A. J. White et al. JOURNAL OF CLINICAL ONCOLOGY
- Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response (CR) post-first-line chemotherapy (FLCT): Preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial.
- (2017) P. Sabbatini et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer (EOC).
- (2017) D. Jelovac et al. JOURNAL OF CLINICAL ONCOLOGY
- AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).
- (2017) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Ovarian Cancer, Version 3.2012
- (2017) Robert J. Morgan et al. Journal of the National Comprehensive Cancer Network
- A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer
- (2012) S. B. Kaye et al. ANNALS OF ONCOLOGY
- Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls
- (2012) Iván Díaz-Padilla et al. Clinical & Translational Oncology
- Ovarian Cancer
- (2012) JESSICA HUNN et al. CLINICAL OBSTETRICS AND GYNECOLOGY
- Bevacizumab in endometrial cancer treatment
- (2012) Matteo Morotti et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Clinical translation of folate receptor-targeted therapeutics
- (2012) Lesheng Teng et al. Expert Opinion on Drug Delivery
- A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer
- (2012) Marcela G. del Carmen et al. GYNECOLOGIC ONCOLOGY
- Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?
- (2012) Georgia A. McCann et al. GYNECOLOGIC ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy in Renal Diseases
- (2012) Ajay Kher et al. MEDICAL CLINICS OF NORTH AMERICA
- Immunotherapies in Dermatologic Disorders
- (2012) Robyn S. Fallen et al. MEDICAL CLINICS OF NORTH AMERICA
- Immunotherapy in Miscellaneous Medical Disorders Graves Ophthalmopathy, Asthma, and Regional Painful Syndrome
- (2012) Michael Gonzales et al. MEDICAL CLINICS OF NORTH AMERICA
- Immunotherapies in Rheumatologic Disorders
- (2012) Anne V. Miller et al. MEDICAL CLINICS OF NORTH AMERICA
- Immunotherapy in Inflammatory Bowel Disease
- (2012) Jatinder P. Ahluwalia MEDICAL CLINICS OF NORTH AMERICA
- Immune Effects of Trastuzumab
- (2012) Marianna Nuti et al. Journal of Cancer
- Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways
- (2012) Donavon Hiss Journal of Oncology
- New drugs for ovarian cancer
- (2011) K. Bell-McGuinn et al. ANNALS OF ONCOLOGY
- The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer
- (2011) Q Sheng et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2011
- (2011) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Biomarkers in the development of anti-angiogenic therapies for ovarian cancer
- (2011) Fharat A. Raja et al. CANCER TREATMENT REVIEWS
- Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View
- (2011) Filippo Bellati et al. Clinical & Developmental Immunology
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
- (2011) N. K. Ibrahim et al. CLINICAL CANCER RESEARCH
- Abagovomab for ovarian cancer
- (2011) Jacobus Pfisterer et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
- (2011) Kazuya Kudoh et al. GYNECOLOGIC ONCOLOGY
- Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group
- (2011) K. Baumann et al. GYNECOLOGIC ONCOLOGY
- Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
- (2011) Marion G. Ott et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
- (2011) Beth Y. Karlan et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
- (2010) J-M Lee et al. BRITISH JOURNAL OF CANCER
- Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
- (2010) Diane Seimetz et al. CANCER TREATMENT REVIEWS
- Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor , in Epithelial Ovarian Cancer: a Phase I Study
- (2010) J. A. Konner et al. CLINICAL CANCER RESEARCH
- Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
- (2010) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Farletuzumab in epithelial ovarian carcinoma
- (2010) Whitney A Spannuth et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Catumaxomab – trifunctional anti-EpCAM antibody used to treat malignant ascites
- (2010) Carsten Bokemeyer EXPERT OPINION ON BIOLOGICAL THERAPY
- The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab
- (2010) M.P. Smerdel et al. GYNECOLOGIC ONCOLOGY
- Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
- (2010) Ernest S. Han et al. GYNECOLOGIC ONCOLOGY
- The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer
- (2010) K.D. Steffensen et al. GYNECOLOGIC ONCOLOGY
- Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study
- (2010) Jean A. Hurteau et al. GYNECOLOGIC ONCOLOGY
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
- (2010) Markus M. Heiss et al. INTERNATIONAL JOURNAL OF CANCER
- Prognostic Importance of Vascular Endothelial Growth Factor-A Expression and Vascular Endothelial Growth Factor Polymorphisms in Epithelial Ovarian Cancer
- (2010) Maja Patricia Smerdel et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel
- (2010) P. Hoskins et al. JNCI-Journal of the National Cancer Institute
- Catumaxomab
- (2010) Rolf Linke et al. mAbs
- The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer
- (2009) C Horlock et al. BRITISH JOURNAL OF CANCER
- Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing
- (2009) Timothy E. Kute et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
- (2009) L. C. Benavides et al. CLINICAL CANCER RESEARCH
- Use of monoclonal antibodies in the treatment of ovarian cancer
- (2009) Seiji Mabuchi et al. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- Pertuzumab
- (2009) S.P. Langdon et al. DRUGS OF THE FUTURE
- Monoclonal antibody therapies for solid tumors
- (2009) Dimiter V Tassev et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
- (2009) Russell J. Schilder et al. GYNECOLOGIC ONCOLOGY
- Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review
- (2009) Filippo Bellati et al. INVESTIGATIONAL NEW DRUGS
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
- (2009) Michael A. Bookman et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
- (2009) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2009) Neil L. Spector et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- (2009) Sharmila Makhija et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
- (2009) Noriyuki Katsumata et al. LANCET
- Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity
- (2009) Y. Nagumo et al. MOLECULAR CANCER RESEARCH
- Functional Folate Receptor Alpha Is Elevated in the Blood of Ovarian Cancer Patients
- (2009) Eati Basal et al. PLoS One
- Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges
- (2009) Doris R. Siwak et al. Journal of Oncology
- Antiangiogenic drugs in ovarian cancer
- (2008) G C Kumaran et al. BRITISH JOURNAL OF CANCER
- Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab
- (2008) A. M. Schultheis et al. CLINICAL CANCER RESEARCH
- Approved monoclonal antibodies for cancer therapy
- (2008) Michael Boyiadzis et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Implications of EGFR inhibition in ovarian cancer cell proliferation
- (2008) Shawna L. Bull Phelps et al. GYNECOLOGIC ONCOLOGY
- Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
- (2008) Halla S. Nimeiri et al. GYNECOLOGIC ONCOLOGY
- A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
- (2008) Jason Konner et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study
- (2008) Angeles Alvarez Secord et al. GYNECOLOGIC ONCOLOGY
- Folate receptor alpha as a tumor target in epithelial ovarian cancer
- (2008) Kimberly R. Kalli et al. GYNECOLOGIC ONCOLOGY
- Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
- (2008) Nilofer S. Azad et al. JOURNAL OF CLINICAL ONCOLOGY
- Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
- (2008) Jonathan Berek et al. JOURNAL OF CLINICAL ONCOLOGY
- CA125 Velocity at Relapse is a Highly Significant Predictor of Survival Post Relapse: Results of a 5-year Follow-up Survey to a Randomized Placebo-controlled Study of Maintenance Oregovomab Immunotherapy in Advanced Ovarian Cancer
- (2008) Jonathan S. Berek et al. JOURNAL OF IMMUNOTHERAPY
- The Immune Adjuvant Properties of Front-line Carboplatin-Paclitaxel: A Randomized Phase 2 Study of Alternative Schedules of Intravenous Oregovomab Chemoimmunotherapy in Advanced Ovarian Cancer
- (2008) Patricia Braly et al. JOURNAL OF IMMUNOTHERAPY
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now